Does LURBINECTEDIN Cause Malignant neoplasm progression? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Malignant neoplasm progression have been filed in association with LURBINECTEDIN (ZEPZELCA). This represents 0.9% of all adverse event reports for LURBINECTEDIN.
9
Reports of Malignant neoplasm progression with LURBINECTEDIN
0.9%
of all LURBINECTEDIN reports
3
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LURBINECTEDIN?
Of the 9 reports, 3 (33.3%) resulted in death.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LURBINECTEDIN. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does LURBINECTEDIN Cause?
Death (129)
Disease progression (98)
Off label use (69)
Neutropenia (59)
Nausea (58)
Thrombocytopenia (48)
Fatigue (43)
Febrile neutropenia (39)
Vomiting (37)
Asthenia (36)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LURBINECTEDIN Alternatives Have Lower Malignant neoplasm progression Risk?
LURBINECTEDIN vs LUSPATERCEPT
LURBINECTEDIN vs LUSPATERCEPT-AAMT
LURBINECTEDIN vs LUTEIN
LURBINECTEDIN vs LUTETIUM LU-177
LURBINECTEDIN vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN